Description
Durvalumab is available in India?
Durvalumab is the salt name for the drug sold under the brand name Imfinzi.
- Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- Adults with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- In combination with etoposide and either carboplatin or cisplatin, as first-line treatment for adults with extensive-stage small cell lung cancer.
- In combination with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer (BTC).
- In June 2024, the US FDA approved durvalumab with carboplatin plus paclitaxel, followed by single-agent durvalumab, for adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
- In August 2024, the FDA approved durvalumab with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
- In December 2024, the FDA expanded the indication of durvalumab to include adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- In March 2025, the FDA approved durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer
Who is the CFA, distributor, and retailer for Imfinzi (Durvalumab) Injection in India?
Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for Imfinzi (Durvalumab) Injection in India. It is marketed by AstraZeneca. Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of AstraZeneca products, including advanced cancer treatments.
The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup.
How much do Imfinzi Injection cost in Delhi, India?
Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals
Contact Person: Ms. Himanshi
Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016.
Do you offer any discounts?
Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price.
Prior to consuming any medications, including Durvalumab Injection, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
07 March 2025 | 05:03 AM (IST)
